Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemiaElisabeth Reiter, Peter Kalhs, Christine Mannhalter et al.|Annals of Hematology|1999Cited by 21
165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trialRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Annals of Oncology|2022Cited by 17
Abstract PO2-04-05: FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASESRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Cancer Research|2024Cited by 2